Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood.
We have tested whether tetracyclines (TETs) are able to protect mice from lipopolysaccharide (LPS)-induced shock, a cytokine-mediated inflammatory reaction. Mice, injected with a single dose of tetracycline base (TETb; 1.5, 10 and 20 mg/kg of body weight) or doxycycline (DOXY; 1.5 mg/kg), were significantly protected from a lethal intraperitoneal injection of LPS (500 micrograms per mouse). TETs acted in early events triggered in response to LSP; in fact, they were no longer significantly protective if injected more than 1 h after the injection of endotoxin. LPS-treated mice protected by TETs showed a significant inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin-1 alpha (IL-1 alpha), and nitrate secretion in the blood, events that were directly related with the survival. In mice treated with TETs a significant decrease of inducible nitric oxide synthase (iNOS) activity was observed in spleen and peritoneal cells compared with that detected in mice treated with LPS alone. Furthermore, TETs were found to inhibit NO synthesis by peritoneal macrophages stimulated in vitro with LPS. On the contrary, TETs were unable to decrease the ability of the macrophages to synthesize IL-1 alpha and TNF-alpha in vitro. These results indicate that TETs are not able to act directly on the synthesis of these cytokines, but they may modulate other pathways that could in turn be responsible for the inhibition of IL-1 alpha and TNF-alpha synthesis. Altogether, these results indicate that TETs are advantageous candidates for the prophylaxis and treatment of septic shock in mice, having both antimicrobial activity and the ability to inhibit endogenous TNF-alpha, IL-1 alpha, and iNOS, hence, exerting, potent anti-inflammatory effects.
Milano
S
S
Institute of General Pathology, University of Palermo, Italy.
Arcoleo
F
F
D'Agostino
P
P
Cillari
E
E
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood / Q000378:metabolism*; D015536:Down-Regulation; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D019446:Endotoxemia / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D004790:Enzyme Induction; D005260:Female; D007274:Injections, Intraperitoneal; D007375:Interleukin-1 / Q000097:blood / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000201:enzymology; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009566:Nitrates / Q000097:blood* / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D012772:Shock, Septic / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D013154:Spleen / Q000187:drug effects / Q000201:enzymology; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000900:Anti-Bacterial Agents; D016207:Cytokines; D007375:Interleukin-1; D009566:Nitrates; D014409:Tumor Necrosis Factor-alpha; D019001:Nitric Oxide Synthase; D013752:Tetracycline; D004318:Doxycycline